Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


Published ahead of print on September 24, 2008
J Am Soc Nephrol 19: 2331-2341, 2008
© 2008 American Society of Nephrology
doi: 10.1681/ASN.2008020170

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
ASN.2008020170v1
19/12/2331    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Wu, H.
Right arrow Articles by Chadban, S. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, H.
Right arrow Articles by Chadban, S. J.

BASIC RESEARCH

IL-18 Contributes to Renal Damage after Ischemia-Reperfusion

Huiling Wu*, Melissa L. Craft*, Peng Wang*, Kate R. Wyburn*, Gang Chen*, Jin Ma*, Brett Hambly{dagger} and Steven J. Chadban*

* Collaborative Transplant Research Group, Renal Medicine, Royal Prince Alfred Hospital and Bosch Institute, Faculty of Medicine, University of Sydney, and {dagger} Pathology Discipline, Bosch Institute, School of Medical Science, University of Sydney, Sydney, Australia

Correspondence: Dr. Huiling Wu, Collaborative Transplant Research Group, Room W607, Blackburn Building D06, University of Sydney, NSW 2006, Australia. Phone: +612-9351-2898; Fax: +612-9351-8771; E-mail: huilingw{at}med.usyd.edu.au

Received for publication February 12, 2008. Accepted for publication July 18, 2008.

IL-18 is a proinflammatory cytokine produced by macrophages and other cell types present in the kidney during ischemia-reperfusion injury (IRI), but its role in this injury is unknown. Here, compared with wild-type mice, IL-18–/– mice subjected to kidney IRI demonstrated better kidney function, less tubular damage, reduced accumulation of neutrophils and macrophages, and decreased expression of proinflammatory molecules that are downstream of IL-18. For determination of the relative contributions of leukocytes and parenchymal cells to IL-18 production and subsequent kidney damage during IRI, bone marrow–chimeric mice were generated. Wild-type mice engrafted with IL-18–/– hemopoietic cells showed less kidney dysfunction and tubular damage than IL-18–/– mice engrafted with wild-type bone marrow. In vitro, macrophages produced IL-18 mRNA and protein in response to ischemia. These data suggest bone marrow–derived cells are the key contributors to IL-18–mediated effects of renal IRI. Finally, similar to IL-18–/– mice, pretreatment of wild-type mice with IL-18–binding protein was renoprotective in this model of IRI. In conclusion, IL-18, derived primarily from cells of bone marrow origin, contributes to the renal damage observed during IRI. IL-18–binding protein may have potential as a renoprotective therapy.







HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP